Cargando…
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
BACKGROUND: Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, improve long-term survival, and shorten treatment duration; however, few have been tested clinic...
Autores principales: | Wallis, Robert S, Ginindza, Sibuse, Beattie, Trevor, Arjun, Nishanee, Likoti, Morongwe, Edward, Vinodh A, Rassool, Mohammed, Ahmed, Khatija, Fielding, Katherine, Ahidjo, Bintou A, Vangu, Mboyo D T, Churchyard, Gavin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332197/ https://www.ncbi.nlm.nih.gov/pubmed/33740465 http://dx.doi.org/10.1016/S2213-2600(20)30448-3 |
Ejemplares similares
-
Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial
por: Wallis, Robert S., et al.
Publicado: (2022) -
Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial
por: Chihota, Violet N., et al.
Publicado: (2015) -
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016) -
Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis
por: Auld, Sara C., et al.
Publicado: (2021) -
Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: a prospective cohort study
por: Baik, Yeonsoo, et al.
Publicado: (2023)